Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein C

Procoagulant factor Va (FVa) is inactivated via limited proteolysis at three Arg residues in the A2 domain by the anticoagulant serine protease, activated protein C (APC). Cleavage by APC at Arg306 in FVa causes dissociation of the A2 domain from the heterotrimeric A1:A2:A3 structure and complete loss of procoagulant activity. To help distinguish inactivation mechanisms involving A2 domain dissociation from inactivation mechanisms involving unfavorable changes in factor Xa (FXa) affinity, we used our FVa homology model to engineer recombinant FVa mutants containing an interdomain disulfide bond (Cys609‐Cys1691) between the A2 and A3 domains (A2‐SS‐A3 mutants) in addition to cleavage site mutations, Arg506Gln and Arg679Gln. SDS‐PAGE analysis showed that the disulfide bond in A2‐SS‐A3 mutants prevented dissociation of the A2 domain. In the absence of A2 domain dissociation from the A1:A2:A3 trimer, APC cleavage at Arg306 alone caused a sevenfold decrease in affinity for FXa, whereas APC cleavages at Arg306, Arg506, and Arg679 caused a 70‐fold decrease in affinity for FXa and a 10‐fold decrease in the kcat of the prothrombinase complex for prothrombin without any effect on the apparent Km for prothrombin. Therefore, for FVa inactivation by APC, dissociation of the A2 domain may provide only a modest final step, whereas the critical events are the cleavages at Arg506 and Arg306, which effectively inactivate FVa before A2 dissociation can take place. Nonetheless, for FVa Leiden (Gln506‐FVa) inactivation by APC, A2 domain dissociation may become mechanistically important, depending on the ambient FXa concentration.

[1]  K Fujikawa,et al.  The coagulation cascade: initiation, maintenance, and regulation. , 1991, Biochemistry.

[2]  P. Kraulis.  A program to produce both detailed and schematic plots of protein structures , 1991 .

[3]  K. Koshibu,et al.  The A2 Subunit of Factor VIIIa Modulates the Active Site of Factor IXa* , 1998, The Journal of Biological Chemistry.

[4]  A. Imbriano.  [Blood coagulation]. , 1955, La Semana medica.

[5]  J. Griffin,et al.  The autolysis loop of activated protein C interacts with factor Va and differentiates between the Arg506 and Arg306 cleavage sites. , 2000, Blood.

[6]  J. Kraut,et al.  Directed mutagenesis of dihydrofolate reductase. , 1983, Science.

[7]  K. Mann,et al.  The contribution of bovine Factor V and Factor Va to the activity of prothrombinase. , 1979, The Journal of biological chemistry.

[8]  R. Sauer,et al.  An engineered intersubunit disulfide enhances the stability and DNA binding of the N-terminal domain of lambda repressor. , 1986, Biochemistry.

[9]  C. Esmon.  The subunit structure of thrombin-activated factor V. Isolation of activated factor V, separation of subunits, and reconstitution of biological activity. , 1979, The Journal of biological chemistry.

[10]  J. Griffin,et al.  Binding Site for Blood Coagulation Factor Xa Involving Residues 311–325 in Factor Va* , 1998, The Journal of Biological Chemistry.

[11]  P. Fay,et al.  Human factor VIIIa subunit structure. Reconstruction of factor VIIIa from the isolated A1/A3-C1-C2 dimer and A2 subunit. , 1991, The Journal of biological chemistry.

[12]  D. McRee,et al.  A visual protein crystallographic software system for X11/Xview , 1992 .

[13]  J. Griffin,et al.  Binding sites for blood coagulation factor Xa and protein S involving residues 493–506 in factor Va , 1996, Protein science : a publication of the Protein Society.

[14]  B. Dahlbäck,et al.  Partial glycosylation of Asn2181 in human factor V as a cause of molecular and functional heterogeneity. Modulation of glycosylation efficiency by mutagenesis of the consensus sequence for N-linked glycosylation. , 1999, Biochemistry.

[15]  H C Hemker,et al.  The role of phospholipids and factor Va in the prothrombinase complex. , 1980, The Journal of biological chemistry.

[16]  L. J. Perry,et al.  Disulfide bond engineered into T4 lysozyme: stabilization of the protein toward thermal inactivation. , 1984, Science.

[17]  J. Griffin,et al.  Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V. , 1995, Blood.

[18]  E A Merritt,et al.  Raster3D: photorealistic molecular graphics. , 1997, Methods in enzymology.

[19]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[20]  H. Hemker,et al.  Peptide Bond Cleavages and Loss of Functional Activity during Inactivation of Factor Va and Factor VaR506Q by Activated Protein C (*) , 1995, The Journal of Biological Chemistry.

[21]  A. Rehemtulla,et al.  Importance of individual activated protein C cleavage site regions in coagulation factor V for factor Va inactivation and for factor Xa activation. , 1999, European journal of biochemistry.

[22]  K. Mann,et al.  Activation of human prothrombin by human prothrombinase. Influence of factor Va on the reaction mechanism. , 1987, The Journal of biological chemistry.

[23]  N Srinivasan,et al.  Stereochemical modeling of disulfide bridges. Criteria for introduction into proteins by site-directed mutagenesis. , 1989, Protein engineering.

[24]  K. Mann,et al.  Activated Protein C Cleavage of Factor Va Leads to Dissociation of the A2 Domain* , 1997, The Journal of Biological Chemistry.

[25]  C. Pabo,et al.  Computer-aided model-building strategies for protein design. , 1986, Biochemistry.

[26]  R. Huber,et al.  Crystal structures of the membrane-binding C2 domain of human coagulation factor V , 1999, Nature.

[27]  K. Mann,et al.  Complete cDNA and derived amino acid sequence of human factor V. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[28]  B. Dahlbäck,et al.  Structural investigation of the A domains of human blood coagulation factor V by molecular modeling , 1998, Protein science : a publication of the Protein Society.

[29]  R. Houghten,et al.  Identification of a sequence of human activated protein C (residues 390-404) essential for its anticoagulant activity. , 1991, The Journal of biological chemistry.

[30]  B. Dahlbäck.  Human coagluation factor V purification and thrombin-catalyzed activation. , 1980, Journal of Clinical Investigation.

[31]  C. Esmon.  Regulation of blood coagulation. , 2000, Biochimica et biophysica acta.

[32]  K. Mann,et al.  A model describing the inactivation of factor Va by APC: bond cleavage, fragment dissociation, and product inhibition. , 1999, Biochemistry.

[33]  C. Esmon,et al.  Loss of prothrombin and of factor Xa-factor Va interactions upon inactivation of factor Va by activated protein C. , 1984, The Journal of biological chemistry.

[34]  H. Hemker,et al.  Characterization of two forms of human factor Va with different cofactor activities. , 1993, The Journal of biological chemistry.

[35]  P. Bucher,et al.  Molecular Models for the two Discoidin Domains of Human Blood Coagulation Factor V , 1998 .

[36]  K. Mann,et al.  The mechanism of inactivation of human factor V and human factor Va by activated protein C. , 1994, The Journal of biological chemistry.

[37]  M. Bednarek,et al.  DETECTION OF FACTOR X ACTIVATION IN HUMANS , 1989, Thrombosis and Haemostasis.

[38]  E. Getzoff,et al.  Three-dimensional Model of Coagulation Factor Va Bound to Activated Protein C , 2000, Thrombosis and Haemostasis.

[39]  H. Hemker,et al.  Human factor Va1 and factor Va2: properties in the procoagulant and anticoagulant pathways. , 1997, Biochemistry.

[40]  D. Powers,et al.  In vivo formation and stability of engineered disulfide bonds in subtilisin. , 1986, The Journal of biological chemistry.